QurAlis Corporation




Cambridge, Massachusetts
QurAlis is developing therapeutics to treat Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord. In ALS, nerve cells degenerate, reducing muscle function and causing loss of muscle control. ALS can be traced to mutations in over 25 different genes and is often caused by a combination of multiple sub-forms of the condition. As the average life expectancy of this terminal disease is three years and there is currently no cure, treatments developed by QurAlis have the potential to provide relief to the more than 200,000 people suffering from ALS worldwide.

Dr. Kasper Roet

Stay Tuned

Subscribe to our newsletter and get updates on our portfolio companies.